No direct effect of SGLT2 activity on glucagon secretion-Reference-Cited by-同舟云学术

No direct effect of SGLT2 activity on glucagon secretion

Published:2019-03-22 Issue:6 Volume:62 Page:1011-1023
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Kuhre Rune E.,Ghiasi Seyed M.,Adriaenssens Alice E.,Wewer Albrechtsen Nicolai J.,Andersen Daniel B.,Aivazidis Alexander,Chen Lihua,Mandrup-Poulsen Thomas,Ørskov Cathrine,Gribble Fiona M.,Reimann Frank,Wierup Nils,Tyrberg Björn,Holst Jens J.

Funder

European Union’s Seventh Framework Programme for Research, Technological Development, and Demonstration Activities

Wellcome Trust

Novo Nordisk Foundation

European Research Council

Novo Nordisk Center for Basic Metabolic Research

Lundbeckfonden

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-019-4849-6.pdf

Reference33 articles.

1. Cuypers J, Mathieu C, Benhalima K (2013) SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg 68(4):287–293. https://doi.org/10.2143/ACB.3349

2. Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509–514. https://doi.org/10.1172/JCI70704

3. Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124(2):499–508. https://doi.org/10.1172/JCI72227

4. Martinez R, Al-Jobori H, Ali AM et al (2018) Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy. Diabetes 67(6):1182–1189. https://doi.org/10.2337/db17-1278

5. Bonner C, Kerr-Conte J, Gmyr V et al (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21(5):512–517. https://doi.org/10.1038/nm.3828

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between SGLT2 and systemic blood pressure regulation;Hypertension Research;2024-05-23

2. Mathematical Models of the Effect of Glucagon on Glycemia in Individuals With Type 2 Diabetes Treated With Dapagliflozin;Journal of the Endocrine Society;2024-04-06

3. Dapagliflozin ameliorates myocardial infarction injury through AMPKα-dependent regulation of oxidative stress and apoptosis;Heliyon;2024-04

4. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits;Cardiovascular Research;2024-03-08

5. Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study;Clinical Drug Investigation;2023-11-07